The influence of the selected polymorphisms of the paraoxonase genes on the risk of sporadic Alzheimer’s disease in a Polish population and on the response to treatment of Alzheimer’s disease with acetylocholinesterase inhibitors
paraoxonase ; gene polymorphism ; Alzheimer disease
Alzheimer's disease (AD) is a degenerative disease of the nervous system, for which escalating memory complains and other cognitive dysfunctions are the most characteristic features. Paraoxonases (PON) are proteins, which participate mainly in antyoxidative processes. It was shown that the Q192R, -161C/T, L55M of the PON1 gene and C311S of the PON2 gene polymorphisms may affect the risk of AD and that the response to the acetylocholinesterase inhibitors (AChEI) treatment may be determined by the Q192R polymorphism of the PON1 gene. The aim of this study was to assess the influence of the above mentioned polymorphisms of the PON genes and the APOE gene on the risk of AD and on the response to AChEI treatment in a Polish population. Genetic studies were performed in 360 AD patients and in 354 healthy control subjects. Examinations were carried out with PCR reaction with appropriate restriction enzymes and with real time–PCR method. The influence of the polymorphisms of PON genes and APOE gene on the response to the AChEI treatment was analyzed in 101 AD cases. The study did not confirm the influence of the polymorphisms Q192R, -161C/T, L55M of the PON1 gene and C311S of the PON2 gene on the risk of AD. The study did not reveal the influence of the tested polymorphisms of the PON genes or the polymorphism of the APOE gene on the response to the AChEI treatment. Metaanalyses perfor ; med in the study including all published results containing raw data did not establish the link between the studied polymorphisms and the risk of AD.